2026. EXPLORATION OF HYDROXYL SUBSTITUTED REGORAFENIB DERIVATIVES AS A TYROSINE KINASE INHIBITORS OF LEUKIMIA THROUGH MOLECULAR DOCKING. Frontier in Medical and Health Research. 4, 3 (Mar. 2026), 3863–3874.